Publications
169
Citations
9,211
Est. group size
~1
Recurring co-author estimate
Active years
38
Publishing since 1989
Typically publishes in teams of ~11 · 0% small-team papers (≤3 authors) · across 20 venues
- Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction
JACC Heart Failure · 2026
- Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
European Journal of Heart Failure · 2026
- Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
European Journal of Heart Failure · 2026
- The Use of Durable Medical Equipment in <scp>COURAGE</scp> ‐ <scp>ALS</scp> , a Phase 3, Multicentre, Randomized Clinical Trial for <scp>ALS</scp>
Muscle & Nerve · 2026
- Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
ESC Heart Failure · 2026
- Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
European Journal of Heart Failure · 2026
- Clinical Evaluation of Drug–Drug Interactions With Aficamten
Clinical and Translational Science · 2026
- The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
medRxiv · 2026
- Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis
medRxiv · 2026
- Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
Clinical Pharmacokinetics · 2025
- Clinical Evaluation of the Effect of Aficamten on <scp>QT</scp>/<scp>QTc</scp> Interval in Healthy Participants
Clinical and Translational Science · 2025
- Serum magnesium and outcomes in patients with heart failure and reduced ejection fraction: insights from the GALACTIC-HF trial
European Heart Journal · 2025
- EVALUATION OF CYTOCHROME P450 2C9, 2C19, AND 2D6 INHIBITION ON THE PHARMACOKINETICS OF AFICAMTEN IN HEALTHY PARTICIPANTS
Journal of the American College of Cardiology · 2025
- Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling
CPT Pharmacometrics & Systems Pharmacology · 2025
- Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
Clinical Pharmacokinetics · 2025
- Journal of the American College of Cardiology×23
- Circulation×12
- European Heart Journal×9
- Journal of Cardiac Failure×8
- JACC Heart Failure×6
- Fady I. Malik
Medicine · University of Michigan
- Caroline Coats
Medicine · University of Michigan
- Michael A. Fifer
Medicine · University of Michigan
- Anjali Owens
Medicine · University of Michigan
- Albree Tower‐Rader
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile